Siponimob ( DrugBank: - )

1 disease
告示番号疾患名（ページ内リンク）臨床試験数
13多発性硬化症／視神経脊髄炎1

13. 多発性硬化症／視神経脊髄炎

臨床試験数 : 3,340 /  薬物数 : 2,163 - (DrugBank : 383) / 標的遺伝子数 : 241 - 標的パスウェイ数 : 238
No.TrialIDDate_
enrollment		Date_
registration		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
1EUCTR2020-002700-39-IT
(EUCTR)		15/09/202117/08/2021Efficacy and safety of ofatumumab and siponimod compared to fingolimod in pediatric patients with multiple sclerosis.A 2-year randomized, 3-arm, double-blind, non-inferiority study comparing the efficacy and safety of ofatumumab and siponimod versus fingolimod in pediatric patients with multiple sclerosis followed by an open-labelextension (NEOS). - NEOS Multiple Sclerosis in pediatric patients
MedDRA version: 20.1;Level: PT;Classification code 10028245;Term: Multiple sclerosis;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]		Product Name: siponimob
Product Code: [BAF312]
INN or Proposed INN: siponimob
Other descriptive name: SIPONIMOD FUMARIC ACID
Product Name: Siponimob
Product Code: [BAF312]
INN or Proposed INN: Siponimob
Other descriptive name: SIPONIMOD FUMARIC ACID
Product Name: ofatumumab
Product Code: [OMB157]
INN or Proposed INN: ofatumumab
Product Name: fingolimod
Product Code: [FTY720]
INN or Proposed INN: fingolimob
Other descriptive name: FINGOLIMOD HYDROCHLORIDE
Product Name: Siponimob
Product Code: [BAF312]
INN or Proposed INN: Siponimob		NOVARTIS PHARMA SERVICES AGNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes		95Phase 3Portugal;Serbia;United States;Taiwan;Estonia;Slovakia;Spain;Ukraine;Russian Federation;Israel;Chile;Italy;India;France;Australia;Latvia;Czechia;Guatemala;Turkey;Lithuania;Austria;United Kingdom;Mexico;Canada;Argentina;Brazil;Belgium;Poland;Croatia;Romania;Germany